CL2020002101A1 - Formulaciones de liberación sostenida de ácido bempedoico. - Google Patents

Formulaciones de liberación sostenida de ácido bempedoico.

Info

Publication number
CL2020002101A1
CL2020002101A1 CL2020002101A CL2020002101A CL2020002101A1 CL 2020002101 A1 CL2020002101 A1 CL 2020002101A1 CL 2020002101 A CL2020002101 A CL 2020002101A CL 2020002101 A CL2020002101 A CL 2020002101A CL 2020002101 A1 CL2020002101 A1 CL 2020002101A1
Authority
CL
Chile
Prior art keywords
sustained release
release formulations
bempedoic acid
formulation
bempedoic
Prior art date
Application number
CL2020002101A
Other languages
English (en)
Inventor
Mohamed Abdelnasser
Narendra Dhanraj Lalwani
Stephen Lawrence Pinkosky
Clay Thomas Cramer
Original Assignee
Esperion Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esperion Therapeutics Inc filed Critical Esperion Therapeutics Inc
Publication of CL2020002101A1 publication Critical patent/CL2020002101A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

FORMULACIÓN QUE COMPRENDE ÁCIDO BEMPEDOICO, UN RELLENO, UN DILUYENTE O SOLUBILIZANTE Y UN AGLUTINANTE, EN DONDE LA FORMULACIÓN ES DE LIBERACIÓN SOSTENIDA; Y SU USO PARA TRATAR UNA ENFERMEDAD CARDIOVASCULAR O REDUCIR SU RIESGO. .
CL2020002101A 2018-02-16 2020-08-13 Formulaciones de liberación sostenida de ácido bempedoico. CL2020002101A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862710417P 2018-02-16 2018-02-16
US201862774083P 2018-11-30 2018-11-30

Publications (1)

Publication Number Publication Date
CL2020002101A1 true CL2020002101A1 (es) 2021-02-19

Family

ID=65685995

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020002101A CL2020002101A1 (es) 2018-02-16 2020-08-13 Formulaciones de liberación sostenida de ácido bempedoico.

Country Status (15)

Country Link
EP (1) EP3752133A1 (es)
JP (1) JP2021513987A (es)
KR (1) KR20200123181A (es)
CN (1) CN111971030A (es)
AU (1) AU2019221765A1 (es)
BR (1) BR112020016494A2 (es)
CA (1) CA3091259A1 (es)
CL (1) CL2020002101A1 (es)
IL (1) IL276689A (es)
MX (1) MX2020008527A (es)
PH (1) PH12020551263A1 (es)
RU (1) RU2020129191A (es)
SG (1) SG11202007825XA (es)
TW (1) TW202000191A (es)
WO (1) WO2019161307A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE072061T2 (hu) 2019-06-21 2025-10-28 Esperion Therapeutics Inc Bempedoinsav elõállítási eljárásai
CN111381270B (zh) * 2020-03-06 2023-04-18 广西田东力源宝科技有限公司 一种利用同位素示踪监控肥料分布的方法
ES3017885T3 (en) * 2021-06-02 2025-05-13 Esperion Therapeutics Inc Compositions containing bempedoic acid alone or in combination with tolvaptan for use in a method for treating autosomal dominant polycystic kidney disease (adpkd)
EP4401708A1 (en) 2021-09-13 2024-07-24 Synthon B.V. Pharmaceutical composition of bempedoic acid
WO2023093807A1 (zh) * 2021-11-24 2023-06-01 南京昕瑞再生医药科技有限公司 用于治疗肝脏疾病的化合物和方法
CA3256768A1 (en) * 2022-05-09 2023-11-16 Renata Pharmaceutical (Ireland) Ltd PHARMACEUTICAL COMPOSITION OF BEMPEDOIC ACID

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3995631A (en) 1971-01-13 1976-12-07 Alza Corporation Osmotic dispenser with means for dispensing active agent responsive to osmotic gradient
US3865108A (en) 1971-05-17 1975-02-11 Ortho Pharma Corp Expandable drug delivery device
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4002173A (en) 1974-07-23 1977-01-11 International Paper Company Diester crosslinked polyglucan hydrogels and reticulated sponges thereof
GB1478759A (en) 1974-11-18 1977-07-06 Alza Corp Process for forming outlet passageways in pills using a laser
US4077407A (en) 1975-11-24 1978-03-07 Alza Corporation Osmotic devices having composite walls
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
US4111202A (en) 1976-11-22 1978-09-05 Alza Corporation Osmotic system for the controlled and delivery of agent over time
US4207893A (en) 1977-08-29 1980-06-17 Alza Corporation Device using hydrophilic polymer for delivering drug to biological environment
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4519801A (en) 1982-07-12 1985-05-28 Alza Corporation Osmotic device with wall comprising cellulose ether and permeability enhancer
US4578075A (en) 1982-12-20 1986-03-25 Alza Corporation Delivery system housing a plurality of delivery devices
US4681583A (en) 1982-12-20 1987-07-21 Alza Corporation System for dispersing drug in biological environment
US5019397A (en) 1988-04-21 1991-05-28 Alza Corporation Aqueous emulsion for pharmaceutical dosage form
US5156850A (en) 1990-08-31 1992-10-20 Alza Corporation Dosage form for time-varying patterns of drug delivery
US6919373B1 (en) 1996-11-12 2005-07-19 Alza Corporation Methods and devices for providing prolonged drug therapy
EP2402300B1 (en) 2003-01-23 2016-05-25 Esperion Therapeutics Inc. Hydroxyl compounds and compositions for cholesterol management and related uses
CN101669948A (zh) * 2008-09-11 2010-03-17 北京科信必成医药科技发展有限公司 一种烟酸和洛伐他汀的缓释片及其制备方法
CN103142552A (zh) * 2013-02-22 2013-06-12 广州科的信医药技术有限公司 一种洛伐他汀肠溶缓释微丸胶囊及其制备方法
MA41793A (fr) * 2015-03-16 2018-01-23 Esperion Therapeutics Inc Associations de doses fixes comprenant du etc1002 et une ou plusieurs statines permettant de traiter ou de réduire un risque cardiovasculaire
WO2017023165A1 (en) * 2015-08-04 2017-02-09 Dezima Pharma B.V. Pharmaceutical composition and therapeutic combination comprising a cholesteryl ester transfer protein inhibitor and an atp citrate lyase inhibitor – ampk activator
US20180338922A1 (en) * 2017-05-26 2018-11-29 Esperion Therapeutics, Inc. Fixed dose formulations

Also Published As

Publication number Publication date
BR112020016494A2 (pt) 2020-12-15
KR20200123181A (ko) 2020-10-28
MX2020008527A (es) 2020-09-18
EP3752133A1 (en) 2020-12-23
JP2021513987A (ja) 2021-06-03
CN111971030A (zh) 2020-11-20
AU2019221765A1 (en) 2020-09-10
CA3091259A1 (en) 2019-08-22
PH12020551263A1 (en) 2021-07-05
TW202000191A (zh) 2020-01-01
IL276689A (en) 2020-09-30
SG11202007825XA (en) 2020-09-29
RU2020129191A (ru) 2022-03-16
WO2019161307A1 (en) 2019-08-22

Similar Documents

Publication Publication Date Title
CL2020002101A1 (es) Formulaciones de liberación sostenida de ácido bempedoico.
DOP2022000006A (es) Inhibidores de parp1
CL2020001048A1 (es) Anticuerpos monoclonales contra bcma. (divisional solicitud 201800281)
CL2019002270A1 (es) Conjugados de anticuerpo y fármaco anti-egfr. (divisional solicitud 201803527)
UY38403A (es) Moduladores de la alfa-1 antitripsina
CL2017002727A1 (es) Composiciones de ácido obeticólico y métodos de uso
CL2018003754A1 (es) Derivado de glucagon, conjugado del mismo, composición que comprende el mismo y uso terapéutico del mismo.
MX418110B (es) Dispersiones solidas y composiciones farmaceuticas que comprenden un indano sustituido y metodos para la preparacion y uso de las mismas
CO7160059A2 (es) Formulación líquida
CL2020000334A1 (es) Formas cristalinas de 2-[(2,4-diclorofenil)metil]-4,4-dimetil-isoxazolidin-3-ona.
MX2017012207A (es) Derivados de aceite natural maleatado a manera de ingredientes agroquimicos inertes.
CL2017002214A1 (es) Formulación de combinación de tesofensina y betabloqueante
CL2017002334A1 (es) Combinaciones y formulaciones de dosis fijas que comprenden etc-1002 y una o más estatinas y métodos para tratar o reducir el riesgo de enfermedad cardiovascular
CL2019002218A1 (es) Formulaciones de combinación triple y métodos para tratar o reducir el riesgo de enfermedad cardiovascular.
CL2019003185A1 (es) Formulaciones líquidas estables de protioconazol.
ECSP22012650A (es) Composiciones que comprenden tigolaner para el control de parásitos
UY38031A (es) Hidroxiisoxazolinas y derivados de estos
MX2019010707A (es) Metodos para tratar y/o prevenir queratosis actinica.
MX2022001449A (es) Compuestos de aminoesterol humano ent-03, composiciones relacionadas que comprenden los mismos y metodos para usar los mismos.
CL2019002729A1 (es) Formulaciones de ácido 1-amino-1-ciclopropanocarboxílico.
CO2021002085A2 (es) Composiciones de curcuminoides
UY38017A (es) Polimorfos de 4-[5-(3,5-dicloro-4-fluorofenil)-4,5-dihidro-5-(trifluorometil)-3-isoxazolil]-n-(2-etil-3-oxo-4-isoxazolidinil)-2-metilbenzamida
CL2019002516A1 (es) Composiciones cosméticas para el cuidado de la piel.
CL2020001252A1 (es) Métodos de uso y composiciones que contienen dulaglutida.
EA202192867A1 (ru) Составы с пролонгированным высвобождением